Altimmune, Inc. (ALT)
Altimmune Sets Pemvidutide's Phase 3 MASH Playbook as AUD Data Near
Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company's focus on pemvidutide, its lead metabolic and liver disease drug candidate, and to discuss the planned Phase 3 program in metabolic dysfunction-associated steatohepatitis, or MASH.
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
ALT and the Rise of Dual Agonists Targeting Liver Disease
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
Altimmune NASDAQ: ALT executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, while also awaiting data from related alcohol-associated liver disease programs.
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Altimmune Q1 Earnings Call Highlights
Altimmune NASDAQ: ALT said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the second half of 2026, as the company reported first-quarter financial results and provided updates across its liver disease pipeline.
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.
